following a second resubmission:
fampridine (Fampyra®) is accepted for use within NHSScotland.
Indication under review: For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4-7).
In double-blind phase III studies fampridine, compared with placebo, improved walking ability in adults with multiple sclerosis and walking impairment.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- fampridine (Fampyra)
- SMC ID:
- SMC2253
- Indication:
For the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS [expanded disability status scale] 4 to 7).
- Pharmaceutical company
- Biogen Idec Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 13 April 2020